Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
A phase 2 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 124 participants.
Also called NCT03097107
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 124 participants
- Sponsor
- Zydus Therapeutics Inc.
- Registry
-
NCT03097107
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Suspended
Technical summary
Registry record NCT03097107. Randomized; quadruple masking; primary purpose treatment. Start 2017-04-06 (actual); primary completion 2023-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
- Condition
- Dyslipidemias
- Intervention (Drug)
- Saroglitazar Magnesium 1 mg
- Intervention (Drug)
- Saroglitazar Magnesium 2 mg
- Intervention (Drug)
- Saroglitazar Magnesium 4 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Zydus Therapeutics Inc.
Record details
- Record id
cardio:ct-nct03097107- Content hash
971e71e40c00a7d6270f3118b94eb2b3839e1e5f22b58293f4766474b8e27fcd